Though intravenous mode of delivery dominates the immunoglobulin market, currently the subcutaneous mode of delivery gains popularity due to fewer systemic side-effects and improvement in the quality of life of the patient. In addition, this route is also easier to use for self-administration of immunoglobulin.

According to a new report published by Allied Market Research, titled,"Immunoglobulin Market by Application, Mode of Delivery, Products Type and Geography: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"the immunoglobulin market accounted for $9,972.9 million in 2017, and is projected to reach $16,694.7 million by 2025, registering a CAGR of 6.6% from 2018 to 2025.

Download Sample PDF Brochure at: https://www.alliedmarketresearch.com/request-sample/2586

In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of immunoglobulin market in these regions are the high adoption rate in developed and populous countries such as Japan and U.S. and the presence of large plasma production facilities.

The key companies profiled in the report include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare.

Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the Immunoglobulin market.

Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 towards market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2586